Bayer Ag News, Bayer Ag Quote, BAYZF Quote

Bayer Ag (OP:BAYZF) Delayed: 40.04 --0 (-0%)

Prev. Close

$40.04

Today 6M 1Y 5Y

Open

$40.04

52 Wk High

$135.00

52 Wk Low

$94.95

Day High

$40.04

Day Low

$40.04

P/E

N/A

EPS

$0.00

Volume

252

Friends, Peers and Foes (?): BAYN, BAYRY IPG (more...)

ALERTS | RSS

Jun 2, 2026 08:00 AM Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026
May 30, 2026 05:24 PM ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
May 21, 2026 08:00 AM Bayer to present cancer trial data at ASCO 2026 meeting
May 21, 2026 08:00 AM ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
May 21, 2026 02:30 AM Bayer's KERENDIA gets FDA priority review for type 1 diabetes treatment
May 21, 2026 02:30 AM Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease
May 19, 2026 02:30 AM FDA grants priority review for Bayer's asundexian stroke drug
May 19, 2026 02:30 AM Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
May 18, 2026 08:41 AM FDA grants priority review for Bayer's HYRNUO lung cancer application
May 18, 2026 08:41 AM U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer

Entities mentioned with BAYZF

View All Entities